Timmerman Report

The Timmerman Report is a subscription-based publication that operates independently, delivering timely and comprehensive news and analysis in the biotech sector. It caters to anyone interested in gaining insights into the latest developments in drug creation, diagnostics, genomics, and other medical technologies that are reshaping healthcare. My aim is to uncover true innovations, spot emerging trends, and highlight the key players and market dynamics at play. With over ten years of experience covering the industry—including navigating through two downturns and one and a half growth periods—I provide context to stories that few others can offer. Readers can expect a broad perspective along with a consistent flow of news, in-depth features, and original insights. This thorough reporting can equip you for important meetings, help you find collaborators, seize investment opportunities, recruit promising talent, build relationships with colleagues, or even secure a job. I strive to write in a way that is accessible to everyone: offering insights that specialized readers will appreciate while also being understandable for those who are new to the topic. It’s the kind of clear, insightful journalism that remains relevant and valuable over time.

National, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#820824

United States

#233374

Health/Biotechnology and Pharmaceuticals

#210

Traffic sources

Monthly visitors

Articles

GSK Antibiotic Hits, ORIC Prostate Cancer Drug Shines, & Taysha Goes 10-for-10

1 week ago | timmermanreport.com | Luke Timmerman

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
A New Idea for Cardiovascular Disease & Diabetes: Ethan Weiss & Josh Lehrer on The Long Run

1 week ago | timmermanreport.com | Luke Timmerman

Ethan Weiss and Josh Lehrer are today’s guests on The Long Run. Ethan is the co-founder and chief scientific officer of South San Francisco-based Marea Biosciences. Josh is the CEO. They are seeking to blaze a new trail with a drug to reduce the risk of cardiovascular disease and type 2 diabetes. It’s a monoclonal antibody aimed at ANGPTL4. There are people with a mutation of the gene who have considerably lower levels of triglycerides and remnant cholesterol.
GlycoEra Grabs $130M to Develop Extracellular Degraders for Autoimmunity

1 week ago | timmermanreport.com | Luke Timmerman

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Vigil, Inozyme Acquired, Prime Cuts, & Regeneron Scoops Up 23andMe

2 weeks ago | timmermanreport.com | Luke Timmerman

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Genentech’s Bet on NC, GSK Buys Boston Liver Drug, & Septerna Entices Novo

3 weeks ago | timmermanreport.com | Luke Timmerman

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Biologic Drug Discovery Made Faster: Peyton Greenside on The Long Run

3 weeks ago | timmermanreport.com | Luke Timmerman

Peyton Greenside is today’s guest on The Long Run. Peyton is the co-founder and CEO of San Mateo, Calif.-based BigHat Biosciences. The company was started in 2019 to build on advances in synthetic biology and machine learning to design antibody drugs with a variety of different properties, faster.
Health Deserves A Vision More Capacious Than Dashboard Metrics

1 month ago | timmermanreport.com | David Shaywitz |Luke Timmerman

Consumer health and wellness is experiencing a flurry of activity. The lab testing company Function (motto: “It’s time to own your health”) acquired Ezra, a whole body MRI company promising “the world’s most advanced longevity scan.” Oura, maker of the popular smart ring, recently added an integration for continuous glucose measurement as well as the ability to calculate meal nutrition based on a photo.
NewLimit’s Anti-Aging Bounty, a Twist Spinout, & AI Coming to the FDA

1 month ago | timmermanreport.com | Luke Timmerman

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Tech-Enabled Power To The People: Ingratiating Chatbots and a Virtuous Food App

1 month ago | timmermanreport.com | David Shaywitz |Luke Timmerman

For at least a decade, nearly every tech company has promoted their product as facilitating the “democratization” of something – perhaps “data driven medicine,” or “genetic information” or “access to clinical trials” or “digital health” (all real examples). Like “mission-driven,” “results-oriented,” and “disruptive,” the term “democratization” has become so overused by the tech community that it’s now more of an obligatory buzzword than a meaningful, resonant concept.
Our Collective Hope For AI in Health, Plus Explanatory Models and an Epic Podcast

1 month ago | timmermanreport.com | David Shaywitz |Luke Timmerman

A recent piece by Nathan Price captures our collective hope for AI in health with unusual clarity, even as there remains impassioned disagreement regarding how close these ambitions are to meaningful realization. For context, Price is Professor and Co-Director of the Center for Human Healthspan at the Buck Institute for Research on Aging and CSO of Thorne, a company best known for its supplements, and which is now expanding into testing.